No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Glenmark Pharmaceuticals Limited, along with its associated businesses, specializes in the development, manufacture, and global distribution of pharmaceutical products. The company's market presence spans India, North America, Latin America, Europe, Japan, and other international territories. Its offerings include both branded and generic drug formulations, primarily focused on therapeutic areas such as dermatology, respiratory conditions, and oncology, in addition to manufacturing active pharmaceutical ingredients. Glenmark boasts a robust development pipeline featuring several key candidates: ISB 2001, a BCMA x CD38 x CD3 trispecific antibody in Phase 1 for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist in Phase 1 for chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor also in Phase 1 for solid tumors. Further pipeline assets comprise ISB 1342, a CD38 X CD3 bispecific antibody in Phase 1 for relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, also in Phase 1 for relapsed/refractory multiple myeloma; ISB 880, an IL-1RAP antibody in Phase 1 for autoimmune diseases; and ISB 830, an OX40 antagonist, currently in Phase 2 for atopic dermatitis. Furthermore, Glenmark markets Ryaltris nasal spray for the symptomatic treatment of seasonal allergic rhinitis. Established in 1977, the company is headquartered in Mumbai, India.
www.glenmarkpharma.comNo one on the platform currently holds GLENMARK.BO.
No tracked institution reports a position in GLENMARK.BO as of their last filing.
No one on the platform has traded GLENMARK.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 27.6% | -19.3% | -1.3% | — | — | — |
| Rev. Growth % | 27.1% | 9.2% | ||||
| Profit Margin % | 8.0% | 2.8% | 5.9% | |||
| Free Cash Flow Margin % | 11.4% | -1.4% | 0.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $167.9B | -1.7% | $82.23 | $64.25–$90.05 | — | 10 |
| 2028 | $187.1B | +11.4% | $99.94 | $89.74–$108.87 | — | 9 |
| 2029 | $208.1B | +11.2% | $110.25 | $98.93–$121.60 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $17.30 | $17.11 | -1.1% |
| 2026-06-01 | $18.20 | $10.68 | -41.3% |
| 2026-02-12 | $18.70 | $14.28 | -23.6% |
| 2025-08-13 | $12.90 | $1.66 | -87.1% |
| 2025-05-23 | $12.10 | $8.75 | -27.7% |
| 2025-02-13 | $14.05 | $12.30 | -12.5% |
| 2024-10-24 | $14.70 | $12.55 | -14.6% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| GLENMARK.BOGlenmark Pharmaceuticals Limited | $2369.10 | -1.98% | $684.3B | — |
| ALKEM.BOAlkem Laboratories Limited | $5241.40 | +2.98% | $625.8B | — |
| ALKEM.NSAlkem Laboratories Limited | $5238.50 | +2.97% | $626.3B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1663.00 | -0.74% | $956.5B | — |
| AUROPHARMA.NSAurobindo Pharma Limited |
| $1663.20 |
| -0.99% |
| $957.0B |
| — |
| BIOCON.BOBiocon Limited | $386.20 | -1.21% | $526.5B | — |
| BIOCON.NSBiocon Limited | $384.80 | -1.50% | $525.7B | — |
Source: Financial Modeling Prep · peers by sector/industry